<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062813</url>
  </required_header>
  <id_info>
    <org_study_id>ZMYe</org_study_id>
    <nct_id>NCT03062813</nct_id>
  </id_info>
  <brief_title>Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)</brief_title>
  <acronym>TOHBVGN</acronym>
  <official_title>The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to evaluate the efficacy and safety of Tacrolimus combined with entecavir&#xD;
      antiviral therapy for HBV-associated glomerulonephritis in china. Tacrolimus combined with&#xD;
      entecavir rapidly and effectively induced remission of HBV-GN in Chinese adults. Meanwhile,&#xD;
      Tacrolimus may have a synergistic antiviral effect with entecavir. The study protocol was&#xD;
      reviewed and approved by Guangdong General Hospital's Ethic Committee, and all participants&#xD;
      provided written informed consents. The study will be a prospective,&#xD;
      randomized,controlled,single-blind, multi-centre, withdrawal study conducted by Guangdong&#xD;
      general hospital, Guangdong Academy of Medical Sciences.there will be two phases, phase 1,&#xD;
      Screening and enrolling 112 HBV-GN patients about one year,and phase 2, ongoing follow-up for&#xD;
      24 weeks.The data of all patients will be recorded in the HBV-GN electronic database.Before&#xD;
      the randomisation, All patients will receive entecavir routine antiviral therapy for two&#xD;
      weeks.And then they will be randomized to two different group,the treatment group: Tacrolimus&#xD;
      combined with entecavir antiviral therapy,the control group: The Tacrolimus placebo and&#xD;
      entecavir antiviral therapy. The Tacrolimus target trough concentration was 5-10 ng/mL during&#xD;
      the therapy. The primary outcome variables were the number of patients who reached complete&#xD;
      or partial remission (CR or PR) after the 25 week-treatment. CR was deﬁned as &lt;0.3 g/24 h&#xD;
      proteinuria (UPCR&lt;300mg/g.cr) or lower plus stable renal function (eGFR&gt;50 ml/min/1.73 m2)&#xD;
      and PR as proteinuria 0.3-3.0 g/24 h (UPCR 300-3000mg/g.cr) and 50% lower than baseline&#xD;
      proteinuria plus stable renal function. Secondary outcome variables: 1) The number of&#xD;
      patients who reached complete or partial remission (CR or PR) after the 13 week-treatment. 2)&#xD;
      Serum creatinine (SCr) increased 2 times the baseline levels or 50% lower than the baseline&#xD;
      eGFR(according to chronic kidney disease-EPI (CKD-EPI) )after the 25 week-treatment. 3)Serum&#xD;
      HBV DNA was undetectable(HBV DNA&lt;500copies/ml) at the end of 25 week-treatment. 4) The number&#xD;
      of patients who present acute kidney injury at the end of 25 week-treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate of proteinuria</measure>
    <time_frame>25 weeks</time_frame>
    <description>the number of patients who reached complete or partial remission (CR or PR) after the 25 week-treatment. CR was deﬁned as &lt;0.3 g/24 h proteinuria (UPCR&lt;300mg/g.cr) or lower plus stable renal function (eGFR&gt;50 ml/min/1.73 m2) and PR as proteinuria 0.3-3.0 g/24 h (UPCR 300-3000mg/g.cr) and 50% lower than baseline proteinuria plus stable renal function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate of proteinuria</measure>
    <time_frame>13 weeks</time_frame>
    <description>The number of patients who reached complete or partial remission (CR or PR) after the 13 week-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Scr</measure>
    <time_frame>25 weeks</time_frame>
    <description>SCr increased 2 times the baseline levels or 50% lower than the baseline eGFR(according to CKD-EPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HBV DNA</measure>
    <time_frame>25 weeks</time_frame>
    <description>Serum HBV DNA was undetectable(HBV DNA&lt;500copies/ml) at the end of 25 week-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of acute kidney injury</measure>
    <time_frame>25 weeks</time_frame>
    <description>The number of patients who present acute kidney injury at the end of 25 week-treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Hepatitis B Virus Associated Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Tacrolimus &amp; entecavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo &amp; entecavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus &amp;entecavir</intervention_name>
    <description>HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.</description>
    <arm_group_label>Tacrolimus &amp; entecavir</arm_group_label>
    <other_name>FK506,Prograf, baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo &amp; entecavir</intervention_name>
    <description>HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.</description>
    <arm_group_label>placebo &amp; entecavir</arm_group_label>
    <other_name>baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients aged between 18 and 65 years with HBV-GN;&#xD;
&#xD;
          -  All HBV-GN cases with biopsy-proven;&#xD;
&#xD;
          -  Evidence of chronic HBV infection based on the presence of HBsAg, HBeAg or HBV DNA in&#xD;
             the serum;(HBsAg, HBeAg was positive, HBV DNA ≥10*3 IU/ml). Chronic HBV infection&#xD;
             lasted for six months, and all patients did not receive the antiviral therapy in the&#xD;
             past six months;&#xD;
&#xD;
          -  Proteinuria more than 3.0g/24h, UPCR&gt;3000mg/g.cr, the result will be proofed by at&#xD;
             least two tests;&#xD;
&#xD;
          -  No glucocorticoid and immunosuppressive treatment within the previous 2 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The diagnosis of idiopathic membranous nephropathy(MN), systemic lupus erythematosus,&#xD;
             malignancy, diabetes mellitus, severe infections or any other systemic disease known&#xD;
             to be associated with secondary MN;&#xD;
&#xD;
          -  eGFR&lt;30ml/min.1.73m*2;&#xD;
&#xD;
          -  Renal pathology showed that Tubular atrophy or Interstitial fibrosis was more than&#xD;
             50%;&#xD;
&#xD;
          -  The participant is allergy to tacrolimus, entecavir;&#xD;
&#xD;
          -  History of diabetes mellitus;&#xD;
&#xD;
          -  History of severe heart disease or cerebrovascular diseases;&#xD;
&#xD;
          -  Other active infection such as cytomegalovirus (CMV),Tuberculosis,Hepatitis A virus&#xD;
             (HAV),Hepatitis C virus (HCV),Hepatitis D virus (HDV); Innate or acquired&#xD;
             immunodeficiency; liver cirrhosis, liver malignment tumor;&#xD;
&#xD;
          -  Pregnant, trying to become pregnant or breast feeding;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiming Ye, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangdong General Hospital, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lifen Wang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lixia Xu, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinling Liang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Shi, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong General Hospital, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiming Ye, PHD</last_name>
    <phone>86-13826161678</phone>
    <email>13826161678@139.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lifen Wang, PHD</last_name>
    <phone>86-18022392896</phone>
    <email>15010942109@139.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong General Hospital, Guangdong Academy of Medical Sciences</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liming Yao, bachelor</last_name>
      <phone>86-83827812-20894</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Lai KN, Li PK, Lui SF, Au TC, Tam JS, Tong KL, Lai FM. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med. 1991 May 23;324(21):1457-63.</citation>
    <PMID>2023605</PMID>
  </results_reference>
  <results_reference>
    <citation>Venkataseshan VS, Lieberman K, Kim DU, Thung SN, Dikman S, D'Agati V, Susin M, Valderrama E, Gauthier B, Prakash A, et al. Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course. Medicine (Baltimore). 1990 Jul;69(4):200-16.</citation>
    <PMID>2142748</PMID>
  </results_reference>
  <results_reference>
    <citation>Elewa U, Sandri AM, Kim WR, Fervenza FC. Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract. 2011;119(1):c41-9; discussion c49. doi: 10.1159/000324652. Epub 2011 Jun 15. Review.</citation>
    <PMID>21677438</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang S, Lai FM, Lui YH, Tang CS, Kung NN, Ho YW, Chan KW, Leung JC, Lai KN. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int. 2005 Oct;68(4):1750-8.</citation>
    <PMID>16164651</PMID>
  </results_reference>
  <results_reference>
    <citation>Igarashi T, Shimizu A, Igarashi T, Hanaoka K, Yoshizaki K, Shigemori T, Shimizu S, Komeichi H, Itoh Y. Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy. J Nippon Med Sch. 2013;80(5):387-95.</citation>
    <PMID>24189358</PMID>
  </results_reference>
  <results_reference>
    <citation>Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol. 2012 Feb 28;18(8):821-32. doi: 10.3748/wjg.v18.i8.821. Review.</citation>
    <PMID>22371643</PMID>
  </results_reference>
  <results_reference>
    <citation>Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012 Nov 13;1:e00049. doi: 10.7554/eLife.00049. Erratum in: Elife. 2014;3:e05570.</citation>
    <PMID>23150796</PMID>
  </results_reference>
  <results_reference>
    <citation>Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology. 2014 May;59(5):1726-37. doi: 10.1002/hep.26982. Epub 2014 Apr 1.</citation>
    <PMID>24375637</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF, Li XW, Chen JH, Wang HY; Chinese Nephropathy Membranous Study Group. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010 Mar;339(3):233-8. doi: 10.1097/MAJ.0b013e3181ca3a7d.</citation>
    <PMID>20220333</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, Braun N, Perna A. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol. 2013 May;8(5):787-96. doi: 10.2215/CJN.07570712. Epub 2013 Feb 28. Review.</citation>
    <PMID>23449768</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu J, Zhang W, Xu Y, Shen P, Ren H, Wang W, Li X, Pan X, Chen N. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol. 2013;181:152-62. doi: 10.1159/000348475. Epub 2013 May 8.</citation>
    <PMID>23689577</PMID>
  </results_reference>
  <results_reference>
    <citation>Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007 May;71(9):924-30. Epub 2007 Mar 21.</citation>
    <PMID>17377504</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>February 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B virus, tacrolimus,membranous nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

